Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal (groups A, C, W, Y) conjugate vaccine (tetanus toxoid carrier) + pneumococcal 13-valent conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This combination refers to the co-administration of the quadrivalent meningococcal conjugate vaccine (MenACWY-TT) and the 13-valent pneumococcal conjugate vaccine (PCV13). MenACWY-TT, marketed as MenQuadfi by Sanofi or Nimenrix by Pfizer, is a conjugate vaccine where capsular polysaccharides from Neisseria meningitidis serogroups A, C, W, and Y are covalently linked to a tetanus toxoid carrier protein. PCV13, marketed as Prevnar 13 by Pfizer, contains capsular polysaccharides from 13 serotypes of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) conjugated to a non-toxic mutant of diphtheria toxin (CRM197). The co-administration of these vaccines is common in pediatric and geriatric immunization schedules. Clinical trials have demonstrated that simultaneous administration at separate injection sites maintains the immunogenicity and safety profile of each individual vaccine, providing broad protection against invasive meningococcal and pneumococcal diseases.
- Other names
- meningococcal (groups A, C, W, Y) conjugate vaccine + pneumococcal 13-valent conjugate vaccineMenACWY-TT + PCV13
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)TT (Tetanus toxoid)MenACWY (Neisseria meningitidis capsular polysaccharides serogroups A, C, W, and Y)
Beyond the preview
Go deeper on meningococcal (groups A, C, W, Y) conjugate vaccine (tetanus toxoid carrier) + pneumococcal 13-valent conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal (groups A, C, W, Y) conjugate vaccine (tetanus toxoid carrier) + pneumococcal 13-valent conjugate vaccine.